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Abstract: Neoadjuvant therapy is integral to the treatment of early-stage breast cancer. 
Goals of treatment include surgical downstaging of the tumor, rendering inoperable tumors 
resectable, and de-escalating axillary surgery in those with clinically positive nodes. 
Additionally, response to treatment provides important prognostic information regarding 
risk of recurrence and guides future adjuvant treatment. Although chemotherapy serves as 
the backbone of neoadjuvant treatment, an increased understanding of the tumor’s clinical 
course as well as its molecular and genetic make-up aids in individualizing treatment and 
developing novel agents. This review summarizes current clinical approaches and the future 
direction to the management of breast cancer patients in the neoadjuvant setting. 
Keywords: neoadjuvant chemotherapy, neoadjuvant endocrine therapy, pCR, breast- 
conserving surgery
Introduction
Breast cancer is the most frequently diagnosed cancer and the leading cause of cancer- 
related death in women globally.1 Treatment decisions are tailored based on the size of 
breast cancer, degree of lymph node involvement, expression of the estrogen receptor 
(ER) and progesterone receptor (PR), and expression of the HER2 protein. 
Neoadjuvant therapy refers to the administration of systemic therapy, either chemother-
apy or endocrine therapy, prior to definitive breast surgery. Patients who derive clinical 
benefit from neoadjuvant chemotherapy (NACT) include patients with high-risk breast 
tumors, large breast tumors, and locally advanced tumors, including those initially 
ineligible for surgery. The goals of NACT include rendering inoperable tumors resect-
able, surgical downstaging for patients who prefer breast conservation, and de- 
escalating axillary surgery in those with clinically positive nodes.
Rationale for Neoadjuvant Systemic Therapy Compared to 
Adjuvant Therapy
Early initiation of systemic therapy was thought to improve overall survival (OS) in 
high-risk patients receiving NACT. However, in the Early Breast Cancer Trialists’ 
Collaborative Group (EBCTCG) meta-analysis, no difference was observed in distant 
recurrence rate (38.2% vs 38%, RR 1.02, 0.92–1.14) or breast cancer mortality (34.4% 
vs 33.7%, RR 1.06, 0.95–1.18) in patients treated with NACT compared to adjuvant 
chemotherapy at 15-year follow-up.2 Furthermore, despite NACT leading to a higher 
frequency of breast-conserving therapy (BCT) (65% vs 49%) compared to adjuvant 
chemotherapy, there was also an associated increased risk of local recurrence in 
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patients (21.4% vs 15.9%; RR 1.37, 1.17–1.61). Similarly, 
the NSABP B-18 study showed equivalent disease-free sur-
vival (DFS), distant disease-free survival, and OS in patients 
receiving pre-operative and post-operative chemotherapy 
(OS; p=0.99, 0.70, and 0.83, respectively), however with 
more women able to achieve BCT in the pre-operative che-
motherapy group.3 One group that did experience a superior 
DFS and OS in those receiving NACT was patients who had 
a pathologic complete response (pCR). Altogether, the afore-
mentioned studies suggest NACT provides therapy that is 
equivalent to adjuvant therapy and notably demonstrates 
a survival advantage in those who have a complete response.4
Association of Pathological Complete 
Response with Survival Outcomes
Response to neoadjuvant therapy provides important prognos-
tic information and helps guide adjuvant therapy recommen-
dations. It allows for an in vivo human model system to 
explore the efficacy of chemotherapy and leads to a better 
understanding of breast cancer biology. pCR, as defined by the 
FDA, is the absence of residual invasive cancer on hematox-
ylin and eosin evaluation of the complete resected breast 
specimen and all sampled regional lymph nodes following 
completion of NACT (ypT0/is ypN0).5 pCR has been shown 
to correlate with improved survival as demonstrated in the 
CTNeoBC pooled analysis.6 This pooled analysis of 12 inter-
national trials and 11,955 patients demonstrated improved 
event-free survival (EFS) and OS with ypT0/Tis ypN0 pCR 
with HR of 0.48 and 0.36, respectively. The association with 
pCR and long-term outcomes was strongest in triple-negative 
breast cancer (TNBC) patients (EFS HR 0.24, OS HR 0.16) 
and HER2-positive, hormone-receptor negative patients who 
received trastuzumab (EFS HR 0.15, OS HR 0.08). Several 
other trials have also demonstrated that the subset of ER- 
negative and HER2-positive breast cancers who achieved 
a pCR after NACT have a notable survival advantage when 
compared to those with residual disease.7,8 The presence of 
residual disease after NACT portends an increased risk of 
recurrence and further adjuvant therapy can be given to 
patients with HER2-positive or triple-negative breast cancer 
to prevent distant disease recurrence.
Clinical and Radiological Assessment in 
the Neoadjuvant Approach
Neoadjuvant chemotherapy allows for visualization of 
a marked reduction in tumor size, thus it is critical to 
accurately mark the primary tumor at the time of 
diagnosis. Prior to undergoing NACT, the following is 
required: physical examination, breast imaging including 
ultrasound, mammogram, and core biopsy, and a biopsy of 
the lymph node with clip/marker placement. Prior to each 
cycle of chemotherapy, a physical examination should be 
performed to monitor response to therapy. There are rare 
occasions where the tumor has little response or grows 
despite NACT, necessitating a change in therapy or pro-
ceeding to earlier surgery. Therefore, periodic physical 
examinations are crucial. At the conclusion of therapy, 
repeat breast imaging including a mammogram and ultra-
sound are performed. The following will discuss the key 
indications for neoadjuvant therapy (Table 1).
Hormone Receptor-Positive Breast 
Cancer
Hormone receptor (HR)-positive breast cancer accounts 
for approximately 75% of new breast cancer diagnoses.9 
Most frequently, these patients will receive cytotoxic che-
motherapy for their neoadjuvant treatment, although there 
are situations where NET is preferred over NACT. While 
NACT confers the greatest advantage in HER2-positive 
breast cancer and TNBC, the rates of pCR are lower in 
luminal cancer, averaging 10–20% of cases.5,8 This sug-
gests that luminal cancers are less sensitive to chemother-
apy compared to other subtypes and a potential alternative 
to cytotoxic chemotherapy is NET. A meta-analysis of 20 
studies involving 3490 patients compared combination 
chemotherapy to NET with aromatase inhibitors (AI).10 
Although both groups had a similar clinical response rate 
(OR, 1.08; 95% CI, 0.50–2.35; P=0.85), radiological 
Table 1 Indications for Consideration of Neoadjuvant 
Chemotherapy
*Hormone-receptor positive breast cancer
High-risk HER2-positive breast cancer
High-risk triple-negative breast cancer
Inflammatory breast cancer
Locally advanced tumors breast cancers
Clinically node-positive breast cancers
Patients with contraindications to surgery including pregnancy or 
venous thromboembolism (VTE)
Delayed elective surgical plans due to pandemic or other elective 
procedures
Note: *In certain circumstances.
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response rate (OR, 1.38; 95% CI, 0.92–2.07; P = 0.12), 
and BCS rate (OR, 0.65; 95% CI, 0.41–1.03; P = 0.07), 
there were lower toxicities associated with AI monother-
apy. These results suggest that in the face of similar out-
comes, NET may be a preferred option in light of 
increased tolerability.
Tamoxifen is a long-standing treatment for HR-positive 
breast cancer. However, issues including tamoxifen resis-
tance and serious adverse effects such as thromboembo-
lism and endometrial cancer necessitate the use of other 
viable options. While earlier trials utilized tamoxifen, 
recent studies demonstrate better outcomes with AI in 
postmenopausal women. The P024 trial is the largest trial 
comparing neoadjuvant tamoxifen and letrozole in HR- 
positive postmenopausal women who were ineligible for 
breast-conserving surgery (BCS). Letrozole led to 
a significantly greater objective response rate (ORR) 
(55% vs 36%, p<0.0010) and rate of BCS (45% vs 35%, 
p=0.022) compared to tamoxifen.11 Both the PROACT and 
IMPACT trial compared neoadjuvant tamoxifen and 
anastrozole.12,13 In the PROACT trial, anastrozole was 
superior to tamoxifen (36.6% vs 24.4% p=0.04) based on 
objective response measured by ultrasound evaluation. 
Although there was no difference in ORR between both 
arms in the IMPACT trial, among patients who were not 
BCS candidates at study entry, treatment with anastrozole 
resulted in increased BCS rate compared to the tamoxifen 
arm (46% vs 22%; p=0.03). Based on these enhanced 
outcomes with AI compared to tamoxifen, the ACOSOG 
Z1031 trial was designed to evaluate clinical outcomes 
among the AIs exemestane, letrozole, and anastrozole.14 
In terms of ORR and BCS, there was no significant dif-
ference found between the different types of AIs, suggest-
ing they are largely interchangeable.
Despite the advantages of neoadjuvant AI therapy, 
there are no clear guidelines about the duration of treat-
ment. Although most NET randomized trials have 
a treatment duration of 3 to 4 months based on studies of 
tamoxifen and chemotherapy, there is concern that this 
might not be sufficient to achieve optimal tumor 
shrinkage.15,16 In clinical studies involving the administra-
tion of 12 months of NET, the ORRs ranges from 76.8 to 
95%, and the rate of BCS was 45 to 87.5%.15,17 In con-
trast, the PROACT and IMPACT trials used a duration of 3 
months and reported an ORR of 49.7% and 37%, respec-
tively, and BCS rates of 43% and 44%, respectively.12,13 
Similar results were observed in a study utilizing exemes-
tane therapy that evaluated tumor size at 3 and 6 months.18 
Overall response was 58.7% at 3 months and 68.3% at 
final clinical palpation (p=0.001). The BCS rate increased 
from 61.8% to 70.6% (p=0.012). Although these studies 
demonstrate that long-term NET achieves further tumor 
reduction and increases BCS rates, there are concerns 
that prolonging NET until maximal response increases 
the risk of disease progression. Further studies will need 
to be done to investigate the optimal duration of NET and 
whether outcomes are not jeopardized as a result of che-
motherapy exclusion.
Another area of interest is identifying reliable biomar-
kers for optimal patient selection and measuring treatment 
response to NET. Although pCR rates have been the stan-
dard to measure efficacy of neoadjuvant therapy, they may 
not be as reliable an outcome measure in HR-positive 
tumors. This has led to the development of the preopera-
tive endocrine prognostic index (PEPI) which combines 
Ki-67 level, ER status, pathological tumor size, and node 
status in the surgical specimen following NET.19 Patients 
with a PEPI score of 0 have an extremely low risk of 
relapse and can be exempt from adjuvant chemotherapy. 
Scores of 0, 1–3, and ≥4 corresponded to a risk of relapse 
of 10, 23, and 48% respectively. The PEPI score was 
further validated in the ACOSOG Z1031 trial. Data at 
a median follow-up time of 5.5 years showed a clear 
difference in relapse-free survival with 3.7% of patients 
with PEPI=0 relapsing compared to 15% with PEPI>1 
(recurrence hazard ratio [PEPI = 0 vs PEPI > 0] = 0.35; 
p = 0.14; 95% CI, 0.092 to 0.764).20 The ALTERNATE 
trial aims to assess the validity of Ki-67 level measure-
ment following four-week treatments with anastrozole, 
fulvestrant, or the combination. After the initial treatment, 
women with a Ki-67>10% will be switched to NACT, 
while women with a PEPI=0 will proceed to receive adju-
vant endocrine therapy.21 Between all the treatment arms, 
no discernable differences were reported in endocrine- 
sensitive disease rates (ESDR) or rate of breast- 
conserving surgeries, although recurrence-free survival 
data are still pending.
Other novel agents are being evaluated with regard to 
their ability to improve the efficacy of NET or to overcome 
de novo resistance to NET. One such class of drugs is 
CDK4/6 inhibitors (CDKI) that have been shown to 
enhance the activity of AI in advanced disease. In the 
neoMONARCH and PALLET trials, the combination of 
NET with a CDKI (abemaciclib and ribociclib, respec-
tively) resulted in decreased levels of Ki-67, although 
this did not correspond to a significant improvement in 
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clinical response rate in the PALLET trial.22,23 The 
CORALLEEN trial was a randomized Phase II trial inves-
tigating ribociclib plus letrozole vs chemotherapy in post-
menopausal women with luminal B HR-positive breast 
cancer.24 The proportion of patients achieving a PEPI of 
0 was 22.4% with ribociclib and letrozole and 17.3% with 
chemotherapy, demonstrating the efficacy of NET com-
bined with CDKIs in luminal B patients as well. Further 
research is needed to elucidate the potential role of CDKIs 
in the neoadjuvant setting.
The eventual development of endocrine resistance with 
endocrine therapy has led to increased interest in phospha-
tidylinositol 3-kinase (PI3K) inhibitors, including alpelisib 
and taselisib, due to the involvement of PI3K-AKT-mTOR 
pathway upregulation in endocrine resistance. The 
LORELEI trial is a phase II trial randomizing 334 patients 
with HR-positive breast cancer to neoadjuvant therapy 
with letrozole plus taselib or letrozole alone. The addition 
of taselisib to letrozole was associated with a higher pro-
portion of patients achieving an ORR compared to letro-
zole alone (50% vs 39%, p=0.049).25 These results suggest 
that PI3K inhibitors do have a role in enhancing the 
effectiveness of NET in HR-positive breast cancer.
Another novel therapeutic approach involves immu-
notherapy, which has demonstrated promising results in 
the neoadjuvant treatment of TNBC. Checkmate 7FL 
(NCT04109066) is an ongoing Phase 3 study evaluating 
nivolumab versus placebo in combination with NACT. 
Patients will undergo surgery and receive either nivolumab 
or placebo with endocrine therapy in the adjuvant 
setting.26 Primary endpoints are pCR and event-free survi-
val. KEYNOTE-756 is another phase 3 study utilizing 
neoadjuvant pembrolizumab (versus placebo) and che-
motherapy followed by pembrolizumab (versus placebo) 
plus endocrine therapy in the adjuvant setting.27 However, 
to date, there are no data supporting a role for immu-
notherapy in the treatment of HR-positive tumors.
High-Risk HER2-Positive Breast 
Cancer
HER2-positive breast cancer is an aggressive subtype that 
is due to persistent activation of signaling of the human 
epidermal growth factor receptor 2 (HER2) pathway and 
accounts for 15% of all breast cancers.28 Patients with 
HER2-positive breast cancer who receive NACT have 
a higher rate of pCR with a combination of cytotoxic 
chemotherapy and targeted therapy compared to those 
who receive adjuvant chemotherapy. A 2016 meta- 
analysis of 5800 patients with HER2-positive breast can-
cer receiving NACT showed that those who achieved 
a pCR had an improved OS and event-free survival 
(EFS) compared to those who did not.29 Neoadjuvant 
chemotherapy for HER2-positive breast cancer includes 
administration of chemotherapy, either anthracycline 
based or non-anthracycline based, with anti-HER2 mono-
clonal antibodies (trastuzumab and pertuzumab). It 
remains controversial regarding the use of an anthracy-
cline in the neoadjuvant setting for HER2-positive breast 
cancer.
Historically, anthracycline-based regimens have been 
used for treatment of HER2-positive breast cancer and 
are often reserved for high-risk subgroups such as those 
with lymph node involvement or a young age. In the 
NSABP B-41 study, patients with HER2-positive breast 
cancer were assigned to receive four cycles of doxorubicin 
and cyclophosphamide every three weeks followed by 
weekly paclitaxel-trastuzumab and were found to have an 
overall pCR rate of 49%. In the lymph node-positive 
patients, the pCR rate was 43%.30
Subsequent studies have shown that treatment with an 
anthracycline is not critical. In the TRAIN-2 study, patients 
with early-stage HER2-positive breast cancer were treated 
with adjuvant chemotherapy, either an anthracycline- 
containing regimen or a non-anthracycline-based chemother-
apy, combined with trastuzumab and pertuzumab. The pCR 
rate did not differ significantly between these two arms (67% 
in the anthracycline arm vs 68% in the non-anthracycline 
arm), and the 3-year EFS (94% vs 93%), OS (98% vs 98%) 
were equivalent.31 No subgroup of patients benefited from 
the inclusion of an anthracycline and there were more side 
effects in the anthracycline-containing arm including higher 
rates of febrile neutropenia (10% vs 1%) and a significant 
decline in LVEF (36% vs 22%). In the randomized phase II 
TRYPHAENA study, the nonanthracycline-containing regi-
mens plus trastuzumab and pertuzumab resulted in a pCR of 
64% compared to a pCR of 55% among those treated with an 
anthracycline-based regimen (FEC-THP) containing trastu-
zumab and pertuzumab and also resulted in lesser hematolo-
gic toxicity.32 Given the aforementioned studies, a taxane and 
carboplatin-containing regimen is a reasonable alternative to 
an anthracycline-containing regimen.
In addition to NACT, anti-HER2 therapy is routinely 
added, with trastuzumab representing the first targeted anti- 
HER2 drug. In a meta-analysis of 2000 patients with HER2- 
positive disease, the addition of trastuzumab to NACT 
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increased the pCR from 23 to 40%.8 Similarly, in the phase II 
NOAH trial, patients treated with NACT and trastuzumab 
had an increase in pCR rate to 38% compared to 19% with 
NACT alone.33 Long-term follow-up demonstrated improved 
EFS in the group that received trastuzumab (43 vs 58%; HR 
0.64, 95% CI 0.544–0.930).33 Despite the effectiveness of 
trastuzumab, there are clinical concerns about the develop-
ment of acquired resistance over a period of time. In order to 
eradicate resistance, the addition of pertuzumab to trastuzu-
mab has been investigated. In the Phase 2 NeoSphere trial, 
patients with locally advanced and inflammatory HER2- 
positive breast cancer had a significantly improved pCR in 
the group receiving pertuzumab and trastuzumab plus doc-
etaxel (45.8%) compared to the other three groups who 
received trastuzumab plus docetaxel (29%, p=0.0141), pertu-
zumab plus trastuzumab (16.8%), or pertuzumab and doce-
taxel (24%).34 A meta-analysis of six trials involving 
approximately 2000 patients demonstrated an improved 
pCR rate of 16–19% in patients receiving dual blockade, 
irrespective of the chemotherapy backbone (RR 1.37, 95% 
CI 1.23–1.53, p < 0.0001).35 These findings suggest a role for 
the addition of pertuzumab to NACT and trastuzumab.
For patients with residual disease after neoadjuvant ther-
apy, T-DM1 in the adjuvant setting can decrease the risk of 
recurrence. This recommendation is based on the results of 
the KATHERINE trial, in which 1486 HER2-positive patients 
with residual invasive disease after neoadjuvant therapy with 
a taxane and trastuzumab or dual HER2-blockade were ran-
domized to receive adjuvant T-DM1 or trastuzumab. T-DM1 
administration improved 3-year invasive disease-free survival 
(88% vs 77%; HR =0.50; 95% CI, 0.39–0.64; P<0.001) and 
the distant recurrence as the first invasive-disease event 
(10.5% vs 15.9%).36 For those patients that achieve pCR 
following HER2-directed therapy, adjuvant trastuzumab is 
continued with or without pertuzumab to complete twelve 
months of HER2-directed therapy (Figure 1).
The benefit of adding trastuzumab to the adjuvant 
chemotherapy regimen has been proven in the BCIRG 
006 study which demonstrated that both doxorubicin- 
cyclophosphamide-docetaxel plus trastuzumab (AC-T 
plus trastuzumab) and docetaxel-carboplatin-trastuzumab 
(TCH) were superior to AC-T with respect to DFS (DFS 
at 5 years; 84% AC-T plus trastuzumab vs 81% TCH vs 
75% AC-T). Estimated OS was 92%, 91%, and 87%, 
respectively.37 The APHINITY trial demonstrated an 
improvement in 3-year IDFS with the addition of pertuzu-
mab to adjuvant trastuzumab (94.1% with pertuzumab vs 
93.2% with placebo, HR 0.81, 95% CI 0.66–1.00; 
p=0.045).38 Among patients with LN-positive breast can-
cer, those randomized to receive adjuvant dual HER2 
blockade for 1 year following chemotherapy had improved 
3-year IDFS by 1.8% (92 vs 90.2%, HR 0.77, 95% CI 
0.62–0.96; p=0.02). In the cohort with node-negative dis-
ease, the 3-year rate of invasive disease-free survival 
(IDFS)\was 97.5% in the pertuzumab group and 98.4% 
in the placebo group (HR1.13; 95% CI 0.68–1.86; 
P=0.64). These results suggest that in the adjuvant treat-
ment of HER2-positive patients, dual HER2 blockade with 
Figure 1 Treatment algorithm for adjuvant treatment in HER2+ patients.
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trastuzumab plus pertuzumab is valid options for node- 
positive disease.
The NCCN Guidelines suggest all HER2-positive 
breast cancer should be treated with a combination of 
adjuvant chemotherapy with trastuzumab.39 The majority 
of adjuvant trastuzumab studies incorporated anthracy-
clines with or without taxanes. The decision on the type 
of chemotherapy backbone should be tailored based on the 
risk–benefit ratio for the individual patient. For example, 
in the aforementioned BCIRG 006 trial, although TCH and 
AC-T plus trastuzumab had similar DFS and OS, the 
former showed a more favorable cardiac safety profile.36 
This chemotherapy regimen would be more suitable for 
patients with cardiac risk factors such as hypertension, 
decreased left ventricular ejection fraction, and older age. 
For HER2-positive tumors <2cm (T1a,bN0M0), retrospec-
tive studies not only demonstrate a benefit for the admin-
istration of trastuzumab but also suggest that there is 
a significant risk of relapse and adverse prognosis if trea-
ted with chemotherapy alone.40–43 Therefore, the NCCN 
guidelines do recommend that these patients receive tras-
tuzumab in combination with chemotherapy.
High-Risk Triple-Negative Breast 
Cancer
Triple-negative breast cancer (TNBC) accounts for 15% of 
all breast cancer and is characterized by the lack of expres-
sion of ER, PR, and HER2. This subtype of breast cancer 
tends to be very aggressive with early recurrence and 
worse OS when compared to other breast cancer 
subtypes.44 Neoadjuvant chemotherapy is a standard 
approach for any tumor greater than 2 cm or with lymph 
node involvement. About 35 to 40% of TNBC patients 
who receive NACT have a pCR which is a surrogate 
marker for survival.45 However, patients who do not 
achieve a pCR have poorer outcomes.46 At the 2018 
SABCS meeting, a meta-analysis of 52 studies, including 
over 27,000 patients, demonstrated significantly superior 
5-year EFS and OS in patients with pCR compared with 
residual disease (RD), with the greatest difference in the 
TNBC cohort (90% vs 57%).47
Early TNBC with tumor sizes ≤0.5 cm (T1a) or between 
0.6–1.0 cm (T1b) without lymph node involvement have 
a good prognosis without the addition of chemotherapy. 
A study involving 363 patients with T1a,bN0 TNBC mea-
sured the five-year distant recurrence-free survival (DRFS) 
between patients treated with adjuvant chemotherapy to 
those who were not. Patients with untreated T1a and T1b 
TNBC had a five-year DRFS 93% and 90% compared to 
treated T1a and T1b TNBC DRFS 100% and 96%, 
respectively.48 Therefore, the decision to administer che-
motherapy can be made on a case-by-case basis. However, 
for tumor size >1 cm with or without lymph node involve-
ment, systemic chemotherapy is the recommended backbone 
of treatment. Standard chemotherapy regimens for TNBC 
are a combination of anthracyclines, taxanes, and alkylators. 
The Anthracycline in Breast Cancer (ABC) analysis evalu-
ated anthracycline-based regimens versus six cycles of TC 
in the adjuvant setting and found that overall, patients treated 
with anthracycline did slightly better (four-year IDFS of 
91% vs 88% for TC).49 The benefit of adding the anthracy-
cline was substantial only in node-positive TNBC and HR- 
positive patients with four or more involved nodes. 
Although the ABC trial was performed in the adjuvant 
setting, the results are commonly extrapolated for manage-
ment in the neoadjuvant setting.
Platinum agents such as carboplatin have been investigated 
in the neoadjuvant setting and have consistently been shown to 
improve pCR rates in multiple trials including CALGB 
40,603, GeparSixto, and BrighTNess (Table 2). In the 
CALGB 40,603 study, TNBC patients were randomized to 
receive bevacizumab, carboplatin, or both in combination with 
standard taxane/anthracycline-based NACT.50 Although the 
addition of carboplatin to standard NACT increased rates of 
Table 2 Neoadjuvant Trials in Triple-Negative Patients
Neoadjuvant Regimens with Carboplatin for Triple-Negative Breast Cancer
Trial Phase # of Patients Investigational Arm pCR (%) with Platinum vs without EFS Improved
CALGB 40,603 2 443 T →AC + Bev 54 vs 41 (p=0.003) No
BrighTNess 3 634 T ± V → AC 58 vs 31 (p<0.001) NA
GeparSixto 2 595 T + A+ Bev 53 vs 43 (p=0.015) Yes
GEICAM/2006-03 2 189 EC → T + Cb 30 in both arms NA
Abbreviations: A, anthracycline; Bev, bevacizumab; C, cyclophosphamide; Cb, carboplatin; E, epirubicin; Nab-pac, nabpaclitaxel; pCR, pathologic complete response; T, 
taxane; V, veliparib.
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pCR from 39% to 49%, it did not result in improved 5-year 
EFS and OS. In contrast, the GeparSixto trial demonstrated 
that the addition of carboplatin significantly improved pCR 
(53% vs 43%, p=0.005) which resulted in higher rates of 
3-year EFS (86% vs 76%, HR of 0.60, 95% CI 0.34–0.93).51 
In the BrighTNess study, patients with stage II to III TNBC 
were randomized to weekly paclitaxel with or without carbo-
platin and veliparib (an oral PARP inhibitor) followed by 
doxorubicin and cyclophosphamide. The addition of carbopla-
tin improved the pCR rate from 31% to 58% while the addition 
of veliparib had no effect on pCR rates.52 Long-term outcome 
data of the BrighTNess trial are still pending.
Interestingly, these studies also demonstrate that TNBC 
patients are likely to derive benefit from the addition of 
carboplatin regardless of BRCA status. In BrighTNess, the 
addition of carboplatin increased the pCR rate in BRCA- 
wildtype patients from 29 to 59%, versus an increase from 
41 to 50% in BRCA carriers.51 Additionally, in 
GeparSixto, there was an absolute improvement in DFS 
at 35 months with the addition of carboplatin, which was 
greater in BRCA-wildtype patients (85 versus 74%; HR 
0.53; 95% CI 0.29–0.96), versus in BRCA-mutated 
patients (86 versus 82%).53,54 Although the addition of 
platinum to a NACT regimen leads to higher pCR rates, 
the associated toxicities often necessitating dose reduc-
tions or cycle eliminations and the contradictory long- 
term survival results make it a controversial choice.
The recent approval of immune-checkpoint inhibitors 
(ICI) combined with chemotherapy in programmed death- 
ligand 1 (PD-L1)-positive metastatic TNBC patients has 
prompted interest in their role in the neoadjuvant setting.55 
Three clinical trials have shown promising data about the 
combination of immunotherapy with NACT (Table 3). In 
Investigation of Serial Studies to Predict Your Therapeutic 
Response through Imaging and Molecular Analysis 2 
(I-SPY2), pembrolizumab (a PD-1 inhibitor) was added 
to standard NACT to evaluate its success in a confirmatory 
randomized phase II trial.56 Pembrolizumab tripled the 
estimated pCR rates in TNBC (60% with pembrolizumab 
versus 22% with placebo). The Phase III KEYNOTE-522 
study examined the addition of pembrolizumab to NACT, 
consisting of paclitaxel and carboplatin followed by dox-
orubicin or epirubicin and cyclophosphamide, resulted in 
an improvement in overall pCR rate from 51 to 65% 
(p<0.001).57 However, additional data about EFS are 
pending final analysis. The phase III IMpassion031 trial 
examined the addition of atezolizumab (a PD-L1 inhibitor) 
to NACT with weekly nab-paclitaxel followed by doxor-
ubicin and cyclophosphamide which resulted in improved 
pCR rate from 41 to 58% (p=0.0044).58 Unfortunately, this 
study was not powered to address EFS. Both KEYNOTE- 
522 and IMpassion031 showed improved pCR in the PD- 
L1 positive groups, but there was a treatment effect in both 
the PD-L1 positive and negative groups. Interestingly, the 
NeoTRIPaPDL1 study did not demonstrate statistically 
significant improved pCR rates with the addition of atezo-
lizumab to NACT consisting of nab-paclitaxel and 
carboplatin.59
There has been interest in identifying subsets of TNBC 
patients who may benefit from less chemotherapy due to 
increased sensitivity to specific agents. One subset of 
patients who may respond to targeted therapy and require 
less chemotherapy is those with germline BRCA muta-
tions that are sensitive to poly ADP-ribose polymerases 
(PARP) inhibitors. Olaparib and talazoparib are two PARP 
inhibitors currently approved for patients with metastatic 
breast cancer and germline mutations. A phase II pilot 
study involved 20 patients (10 TNBC) with germline 
BRCA mutations receiving neoadjuvant talazoparib in 
which pCR was achieved in 53% prompting the explora-
tion of the role of PARP monotherapy in this subset of 
patients.
Table 3 Neoadjuvant Trials with Immunotherapy in Triple-Negative Patients
Neoadjuvant Regimens with Immunotherapy in Triple-Negative Breast Cancer






pCR(%) with ICI Versus 
without
I-SPY2 2 250 T → AC Pembrolizumab 60% vs 22%
KEYNOTE-522 3 602 Cb + T → AC Pembrolizumab 65% vs 51% (p<0.001)
IMpassion031 3 333 Nab-pac → AC Atezolizumab 58% vs 41% (p=0.004)
NeoTRIPaPDL1 3 280 Cb + Nab-pac Atezolizumab 44% vs 41% (p=0.66)
Abbreviations: A, anthracycline; Bev, bevacizumab; C, cyclophosphamide; Cb, carboplatin; Nab-pac, nabpaclitaxel; pCR, pathologic complete response; T, taxane; V, 
veliparib.
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In the case of residual disease after NACT, adjuvant 
capecitabine is another potential therapy to further reduce 
the risk of breast cancer recurrence. The CREATE-X trial 
randomized 910 patients with HER2-negative disease trea-
ted with standard NACT and with residual disease to 
adjuvant capecitabine for six to eight cycles versus obser-
vation only.60 Adjuvant radiotherapy was given if indi-
cated. Full analysis demonstrated an improvement in 
5-year DFS from 69.8% to 56.1% with capecitabine in 
the TNBC subset. These findings further support the use 
of NACT instead of adjuvant chemotherapy in TNBC 
patients, as those patients who achieve pCR have 
improved outcomes and those that do not achieve pCR 
clearly can benefit from the addition of adjuvant 
capecitabine.
Inflammatory Breast Cancer
Inflammatory breast cancer (IBC) is a rare form of breast 
cancer comprising 2.5% of all breast cancers in the United 
States.61 The main role of neoadjuvant therapy in the 
setting of IBC is to be able to surgically treat with mod-
ified radical mastectomy without leaving positive margins, 
thereby limiting the risk of systemic metastases.
The current standard of neoadjuvant therapy in IBC is 
determined by the subtype of breast cancer with regard to 
expression of ER, PR, and HER2. Neoadjuvant therapy 
for ER-positive and TNBC remains anthracycline and 
taxane-based chemotherapy. In a large retrospective 
study, of the 178 IBC patients treated with anthracycline- 
based chemotherapy followed by local treatment with 
irradiation, with or without mastectomy, 15-year survival 
was the greatest in patients who accomplished pCR 
(44%), versus partial response (31%).62 In a cohort 
study of 68 patients with IBC, treatment with either 
NACT consisting of FEC (cyclophosphamide, epirubicin 
and 5-fluorouracil) or FAC (cyclophosphamide, doxorubi-
cin and 5-fluorouracil), followed by surgery, adjuvant 
therapy, and radiotherapy resulted in overall 5-year survi-
val rate of 44% and 10-year survival of 32%.63 These 
results confirmed that IBC patients obtained significant 
long-term survival benefit from combined-modality treat-
ment. The standard of care in neoadjuvant treatment of 
IBC is a sequential regimen using anthracyclines then 
taxanes.
Given that IBC has a higher proportion of HER2- 
positive tumors as compared to noninflammatory cancers 
or other locally advanced cancers, anti-HER2 treatments 
have an integral role in the neoadjuvant setting. In the 
NeOAdjuvant Herceptin (NOAH) trial, HER2-positive 
IBC had a pCR of 54.8% after treatment with neoadjuvant 
trastuzumab combined with chemotherapy.64 A subsequent 
subgroup analysis comparing patients that received 
a combination of trastuzumab plus NACT vs NACT 
alone had a better 5-year event-free survival (64% vs 
24%) and 5-year OS (74% vs 44%).33
Locally Advanced Breast Cancer or 
Clinically Node-Positive Disease 
Patients with T3 or T4 breast lesions or with multiple 
axillary lymph nodes involved are candidates for NACT 
as they are often not amenable to upfront resection and 
they would not be candidates for breast conservation. 
Additionally, patients with limited clinically node- 
positive disease are also eligible for NACT, as it often 
converts cN1 patients to pN0, especially in patients with 
aggressive subtypes. 
Neoadjuvant therapy was initially pursued in patients with 
locally advanced breast cancers, typically at least T3 (≥5 cm in 
largest dimension), in which only larger, involved surgeries 
would have been considered.  Patients with locally advanced 
breast cancers or inoperable breast cancers have traditionally 
been excluded from larger randomized control trials assessing 
the effect of neoadjuvant therapy on surgical options and 
outcomes. However, neoadjuvant therapy in this group 
of patients is recommended by major cancer society governing 
bodies ASCO65 and NCCN.39 The rationale is that neoadju-
vant systemic therapy can lead to downstaging of the primary 
tumor to increase operability or potential cosmesis of breast- 
conserving therapy (BCT), as well as to more rapidly treat 
subclinical distant micrometastases. However, there have 
been several large randomized controlled trials that have 
clearly demonstrated improved rates of BCT therapy with 
neoadjuvant therapy compared to adjuvant therapy in earlier 
stage operable breast cancers.  This data has been extended 
to guide management of more locally advanced disease.  
NSABP B-18 randomized 1523 women with stage I– 
II disease to either pre-operative or post-operative AC.66 It 
found that more patients receiving neoadjuvant ther-
apy were able to receive lumpectomy, compared to those 
receiving adjuvant therapy (67.8% vs 59.8%).  The ECTO 
trial assessed patients with primary operable breast cancer 
(T2–3N0–1M0) who received neoadjuvant systemic therapy 
(in this case AT x 4 cycles, followed by CMF for 4 cycles) 
and compared them to those receiving surgery followed by 
adjuvant therapy.67 There was a significant reduction in the 
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requirement for mastectomy in patients who received neoad-
juvant therapy.  65% of patients receiving neoadjuvant therapy 
were able to receive BCS compared to 34% of women in the 
primary surgery arms (p<0.001).  
More importantly, several studies have performed second-
ary analyses which demonstrated that patients who were not 
candidates for breast-conserving surgery at diagnosis were 
able to become candidates for BCS after neoadjuvant 
therapy.   In the CALGB 40,601 study, breast-conserving sur-
gery candidacy was assessed of patients with stage II–III 
HER2+ breast cancer before and after neoadjuvant 
therapy.68   43% of the patients who were not initially candi-
dates for BCS converted to candidates for BCS after neoadju-
vant therapy.  In the more recent BrighTNess RCT, 604 
patients with stage II–III TNBC were assessed for BCS can-
didacy before and after neoadjuvant therapy.69 Of the 141 
patients who were deemed BCS ineligible at baseline, 53.2% 
then converted to BCS eligible after neoadjuvant therapy with 
ACT ± carboplatin and/or veliparib.   
Traditionally, the standard approach to clinically node- 
positive breast cancer is with axillary lymph node dissec-
tion (ALND).  However, ALND has been associated with 
higher surgical complications and long-term symptomatic 
risks of lymphedema, limited mobility in that extremity, 
and neuropathy which can greatly lessen quality of 
life.  Currently, randomized controlled trials examining 
the question of whether neoadjuvant therapy can decrease 
the need for ALND are ongoing.  However, guidelines still 
recommend upfront systemic therapy for clinically node- 
positive disease to permit for less extensive surgery on the 
axilla based on data from other trials.1  In a prospective 
study of 288 node-positive stage II–III breast cancer 
patients receiving neoadjuvant therapy, patients who were 
clinically node-negative after treatment were candidates 
for sentinel lymph node biopsy (SLNB).70  68% of those 
who underwent surgery became clinically node-negative 
after NACT and were able to undergo an SLNB as 
opposed to ALND.  Of the 128 SLNB cases, 48% were 
able to avoid a subsequent ALND, which supports the role 
of neoadjuvant therapy for reducing the need for ALND 
among patients with metastases.  One significant concern 
with neoadjuvant therapy followed by SLNB instead of 
ALND in patients who were baseline clinically node- 
positive is the potential false-negative rate of 
SLNB; i.e. no evidence of nodal metastases on sufficient 
SLNB, but later found to have nodal metastases on an 
ALND.  The ACOSOG Z1071 trial specifically addressed 
this concern.  The initial multi-institutional trial 
demonstrated that the false-negative rate of SLNB after 
NACT was 12.6%.71  However, a secondary analysis of the 
study showed that in patients who had a clip placed in the 
positive node at the initial biopsy and had an SLNB of at 
least 2 nodes, that the clip was recovered within the SLN 
specimen 83.7% of the time,72  Another study showed that 
in 118 patients undergoing SLNB followed by ALND, that 
if the clipped node was included in the SLNB that the 
false-negative rate decreased greatly, from 10.1% to 
1.4%.73  Thus, a reasonable approach to clinically node- 
positive disease is to place a clip during biopsy, pursue 
neoadjuvant therapy, and then if then downstaged to clini-
cally node-negative disease move forward with an 
SLNB.  SLNB should include the clip to decrease the 
false-negative rate.  If SLNB is positive for nodal metas-
tasis, then ALND can be performed.  If SLNB is nega-
tive, potential complications and sequelae of ALND can be 
avoided.
Patients with Contraindications for 
Surgery 
Neoadjuvant chemotherapy or endocrine therapy may be 
a suitable option for patients who have contraindications to 
undergo surgery at the time of diagnosis or in situations in 
which delays in elective surgeries are encountered or 
necessitated, such as during a pandemic, during pregnancy 
or after a recent venous thromboembolism.  
There are several absolute contraindications to upfront 
surgery and/or radiation. These typically are due to inabil-
ity to achieve appropriate margin control with BCS or 
inability of the patient to tolerate radiation therapy.  
Some of the absolute contraindications to initial BCS are 
multicentric disease where tumors are located in different 
quadrants of the breast and patients with diffuse malig-
nant-appearing microcalcifications not confined to a single 
localized area.  Due to the multicentric or diffuse nature of 
these presentations, a lumpectomy or smaller surgery is 
often not able to be completed until downstaging by 
neoadjuvant therapy.  Patients who have had prior radia-
tion therapy to the affected breast also have an absolute 
contraindication to BCT.   Frequently, these patients have 
had previous radiation in the setting of treatment of 
Hodgkin’s Lymphoma or previous breast cancer.  If they 
were considered for further radiation, these patients would 
receive unacceptably high doses of radiation, making 
BCT infeasible.  An additional absolute contraindication 
to BCT is a patient diagnosed in the first or second 
Breast Cancer: Targets and Therapy 2021:13                                                                             submit your manuscript | www.dovepress.com                                                                                                                                                                                                                       
DovePress                                                                                                                         
207
Dovepress                                                                                                                                                           Hyder et al
trimester of pregnancy and where a pregnancy termination 
is not desired or feasible.  This is because therapeutic 
radiation during pregnancy is teratogenic to the fetus.  
Typically, radiation is given within 3–8 weeks of lumpect-
omy.  Waiting a longer period of time, such as greater than 
20 weeks, can significantly decrease local recurrence-free 
survival and breast cancer-specific survival, as compared 
to waiting 4–8 weeks after therapy.74  In this situation, it is 
reasonable to consider neoadjuvant therapy.  For patients 
diagnosed in the third trimester, they may be able to move 
forward with upfront BCT as radiation therapy may be 
administered after delivery of the baby.  
Some relative contraindications to initial BCT are 
those that are related to vascular changes of the patient, 
which increase the risk of complications or the risk of 
inadequate cosmesis of the breast.  Traditionally, patients 
with collagen vascular disease (CVD) have been classified 
as having a relative contraindication to BCT due to poor 
vasculature and cutaneous friability, making radiation 
complications more likely.  However, there have been 
multiple studies that have shown that the increased risk 
of radiation complications of CVD patients is only in 
scleroderma patients.75,76 This is not seen in other patients 
with CVD. Another relative contraindication to initial sur-
gery is an insufficient tumor-to-breast ratio (i.e. a large 
tumor in a small breast), which would not allow for 
acceptable cosmetic result.77  In these cases, neoadjuvant 
systemic therapy can allow for downstaging of the tumor 
and allow for a more amenable tumor to breast size ratio 
and improved cosmetic outcome.   Other relative contra-
indications to primary surgery and radiation may be addi-
tional medical or social issues; such as recent 
thromboembolism requiring anticoagulation, temporary 
medical unfitness, or delay of non-urgent procedures 
given medical system strain during a pandemic.  In these 
cases, NACT or NET – if clinically appropriate – can help 
to manage and treat the breast cancer until the patient is 
able to receive surgery and radiation.  
Conclusion
The landscape of neoadjuvant therapy continues to evolve. 
Advances in systemic therapies administered in the neoad-
juvant setting have resulted in increased suitability for 
subsequent surgeries. Clinical trials continue to investigate 
other therapies (ICI, PI3K inhibitors, mTOR inhibitors) 
that can be utilized for the different subtypes of breast 
cancer. The I-SPY2 provides a unique opportunity to eval-
uate novel agents added to standard neoadjuvant therapy in 
small study populations with an earlier endpoint of pCR. 
This allows investigational drugs with a high probability 
of efficacy to move on to phase III studies more rapidly.78 
Another area of interest is developing biomarkers that can 
be predictors and prognosticators of response to neoadju-
vant treatment. Biomarkers (TIL, tumor PD-L1, germline 
BRCA) can identify patients likely to achieve pCR, predict 
who can forgo surgery, and detect minimal residual disease 
(ctDNA and circulating tumor cells). Understanding the 
clinical, genetic, and molecular profiles in breast cancer 
leads to the development of validated predictive and prog-
nostic tools that helps individualize treatment plans for 
these patients.
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